1
|
Hassan F, Saleem A, Samuel SS, Sarfraz Z, Sarfraz A, Sarfraz M, Kc M. Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy. Medicine (Baltimore) 2023; 102:e33978. [PMID: 37335635 DOI: 10.1097/md.0000000000033978] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/21/2023] Open
Abstract
BACKGROUND Over 75% of menopausal women experience vasomotor symptoms (VMS), such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is limited data on non-hormonal therapies to alleviate them. METHODS PubMed, Cochrane, Scopus, Ovid, Web of Science, and ClinicalTrials.Gov were searched for relevant studies. The search was performed using the following keywords, which were customized to suit the specific databases/registers: menopause, women, neurokinin 3, and/or Fezolinetant. The search was conducted until December 20, 2022. This systematic review was conducted in compliance with the PRISMA Statement 2020 guidelines. RESULTS A total of 326 records were found, with 10 studies (enrolling 1993 women) selected for inclusion. The women received 40-mg doses of NK1/3 receptor antagonists twice daily, with follow-ups at 1 to 3 weeks. Moderately strong evidence was found suggesting that NK1/3 receptor antagonists can help limit the frequency and severity of hot flashes in menopausal women. CONCLUSION While the results should be interpreted with caution until further clinical trials validate the efficacy and safety of NK1/3 receptor antagonists among menopausal women, these findings suggest that they are promising targets for future pharmacological and clinical studies in addressing vasomotor symptoms.
Collapse
Affiliation(s)
| | - Anam Saleem
- Punjab Medical College, Faisalabad, Pakistan
| | | | | | | | | | - Manish Kc
- KIST Medical College, Lalitpur, Nepal
| |
Collapse
|
2
|
Nkondo-Ndaba MP, Joubert PM, Ballyram T, van Rensburg CJ. Influence of first- and second-generation antipsychotics on anthropometric parameters of male psychiatric patients. S Afr J Psychiatr 2022. [DOI: 10.4102/sajpsychiatry.v2i0.1772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Shi M, Tang J, Yang C, Guo G, Ou H, Chen W. Pimavanserin, a 5-hydroxytryptamine 2A receptor inverse agonist, reverses prepulse inhibition deficits in the nucleus accumbens and ventral hippocampus. Neuropharmacology 2021; 201:108838. [PMID: 34666074 DOI: 10.1016/j.neuropharm.2021.108838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 10/09/2021] [Accepted: 10/11/2021] [Indexed: 10/20/2022]
Abstract
Prepulse inhibition (PPI) is disrupted in many neuropsychiatric diseases. Although the inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptors, pimavanserin, alleviates PPI deficits in rodents, the precise mechanisms and critical brain areas in the reversal effect of 5-HT2A receptor inverse agonists remain unclear. The present study aimed to investigate the critical brain areas responsible for the reversal effect of the 5-HT2A receptor inverse agonist on PPI deficits in male mice. The results showed that intraperitoneal administration of pimavanserin was found to improve normal PPI behavior and reverse PPI deficits elicited by the dopamine D1/D2 receptor nonselective agonist, pergolide. Further, local infusion of pimavanserin into the nucleus accumbens and ventral hippocampus reversed PPI deficits, whereas the same manipulation in the medial prefrontal cortex or ventral tegmental area did not reverse PPI deficits. Overall, the nucleus accumbens and ventral hippocampus are the critical brain areas responsible for the reversal effect of 5-HT2A inverse agonists on PPI deficits. Such findings contribute to the extensive exploration of the accurate molecular and neural mechanisms underlying the antipsychotic effects of 5-HT2A receptor inverse agonists, especially the neural circuits modulated by 5-HT2A receptor activity.
Collapse
Affiliation(s)
- Mengwen Shi
- Key Laboratory of Cognition and Personality Southwest University, Ministry of Education, Chongqing, China; Faculty of Psychology, Southwest University, Chongqing, China
| | - Jiaxin Tang
- Key Laboratory of Cognition and Personality Southwest University, Ministry of Education, Chongqing, China; Faculty of Psychology, Southwest University, Chongqing, China
| | - Chengmei Yang
- Key Laboratory of Cognition and Personality Southwest University, Ministry of Education, Chongqing, China; Faculty of Psychology, Southwest University, Chongqing, China
| | - Guanlong Guo
- Key Laboratory of Cognition and Personality Southwest University, Ministry of Education, Chongqing, China; Faculty of Psychology, Southwest University, Chongqing, China
| | - Huaxing Ou
- Key Laboratory of Cognition and Personality Southwest University, Ministry of Education, Chongqing, China; Faculty of Psychology, Southwest University, Chongqing, China
| | - Weihai Chen
- Key Laboratory of Cognition and Personality Southwest University, Ministry of Education, Chongqing, China; Faculty of Psychology, Southwest University, Chongqing, China.
| |
Collapse
|
4
|
Caldara M, Marmiroli N. Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications. Pharmaceuticals (Basel) 2021; 14:ph14090915. [PMID: 34577614 PMCID: PMC8470654 DOI: 10.3390/ph14090915] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 09/03/2021] [Accepted: 09/08/2021] [Indexed: 12/13/2022] Open
Abstract
The spreading of antibiotic resistance is responsible annually for over 700,000 deaths worldwide, and the prevision is that this number will increase exponentially. The identification of new antimicrobial treatments is a challenge that requires scientists all over the world to collaborate. Developing new drugs is an extremely long and costly process, but it could be paralleled by drug repositioning. The latter aims at identifying new clinical targets of an “old” drug that has already been tested, approved, and even marketed. This approach is very intriguing as it could reduce costs and speed up approval timelines, since data from preclinical studies and on pharmacokinetics, pharmacodynamics, and toxicity are already available. Antidepressants and antipsychotics have been described to inhibit planktonic and sessile growth of different yeasts and bacteria. The main findings in the field are discussed in this critical review, along with the description of the possible microbial targets of these molecules. Considering their antimicrobial activity, the manuscript highlights important implications that the administration of antidepressants and antipsychotics may have on the gut microbiome.
Collapse
Affiliation(s)
- Marina Caldara
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze 11/A, 43124 Parma, Italy;
- Interdepartmental Center SITEIA.PARMA, University of Parma, Parco Area delle Scienze 181/A, 43124 Parma, Italy
- Correspondence:
| | - Nelson Marmiroli
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze 11/A, 43124 Parma, Italy;
- Interdepartmental Center SITEIA.PARMA, University of Parma, Parco Area delle Scienze 181/A, 43124 Parma, Italy
- Italian National Interuniversity Consortium for Environmental Sciences (CINSA), University of Parma, 43124 Parma, Italy
| |
Collapse
|
5
|
Carvalho RL, de Miranda AS, Nunes MP, Gomes RS, Jardim GAM, Júnior ENDS. On the application of 3d metals for C-H activation toward bioactive compounds: The key step for the synthesis of silver bullets. Beilstein J Org Chem 2021; 17:1849-1938. [PMID: 34386103 PMCID: PMC8329403 DOI: 10.3762/bjoc.17.126] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 06/28/2021] [Indexed: 01/24/2023] Open
Abstract
Several valuable biologically active molecules can be obtained through C-H activation processes. However, the use of expensive and not readily accessible catalysts complicates the process of pharmacological application of these compounds. A plausible way to overcome this issue is developing and using cheaper, more accessible, and equally effective catalysts. First-row transition (3d) metals have shown to be important catalysts in this matter. This review summarizes the use of 3d metal catalysts in C-H activation processes to obtain potentially (or proved) biologically active compounds.
Collapse
Affiliation(s)
- Renato L Carvalho
- Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais - UFMG, CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Amanda S de Miranda
- Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais - UFMG, CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Mateus P Nunes
- Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais - UFMG, CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Roberto S Gomes
- Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, United States
| | - Guilherme A M Jardim
- Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais - UFMG, CEP 31270-901, Belo Horizonte, MG, Brazil
- Centre for Excellence for Research in Sustainable Chemistry (CERSusChem), Department of Chemistry, Federal University of São Carlos – UFSCar, CEP 13565-905, São Carlos, SP, Brazil
| | - Eufrânio N da Silva Júnior
- Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais - UFMG, CEP 31270-901, Belo Horizonte, MG, Brazil
| |
Collapse
|
6
|
Sullivan LC, Clarke WP, Berg KA. Atypical antipsychotics and inverse agonism at 5-HT2 receptors. Curr Pharm Des 2016; 21:3732-8. [PMID: 26044975 DOI: 10.2174/1381612821666150605111236] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Accepted: 06/04/2015] [Indexed: 11/22/2022]
Abstract
It is now well accepted that receptors can regulate cellular signaling pathways in the absence of a stimulating ligand, and inverse agonists can reduce this ligand-independent or "constitutive" receptor activity. Both the serotonin 5-HT2A and 5-HT2C receptors have demonstrated constitutive receptor activity in vitro and in vivo. Each has been identified as a target for treatment of schizophrenia. Further, most, if not all, atypical antipsychotic drugs have inverse agonist properties at both 5-HT2A and 5-HT2C receptors. This paper describes our current knowledge of inverse agonism of atypical antipsychotics at 5-HT2A/2C receptor subtypes in vitro and in vivo. Exploiting inverse agonist properties of APDs may provide new avenues for drug development.
Collapse
Affiliation(s)
| | | | - Kelly A Berg
- Department of Pharmacology - MS 7764, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
| |
Collapse
|
7
|
Lemercier CE, Schulz SB, Heidmann KE, Kovács R, Gerevich Z. Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony. Front Pharmacol 2016; 6:297. [PMID: 26779018 PMCID: PMC4702013 DOI: 10.3389/fphar.2015.00297] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2015] [Accepted: 12/03/2015] [Indexed: 11/13/2022] Open
Abstract
Cortical gamma oscillations are associated with cognitive processes and are altered in several neuropsychiatric conditions such as schizophrenia and Alzheimer’s disease. Since dopamine D3 receptors are possible targets in treatment of these conditions, it is of great importance to understand their role in modulation of gamma oscillations. The effect of D3 receptors on gamma oscillations and the underlying cellular mechanisms were investigated by extracellular local field potential and simultaneous intracellular sharp micro-electrode recordings in the CA3 region of the hippocampus in vitro. D3 receptors decreased the power and broadened the bandwidth of gamma oscillations induced by acetylcholine or kainate. Blockade of the D3 receptors resulted in faster synchronization of the oscillations, suggesting that endogenous dopamine in the hippocampus slows down the dynamics of gamma oscillations by activation of D3 receptors. Investigating the underlying cellular mechanisms for these effects showed that D3 receptor activation decreased the rate of action potentials (APs) during gamma oscillations and reduced the precision of the AP phase coupling to the gamma cycle in CA3 pyramidal cells. The results may offer an explanation how selective activation of D3 receptors may impair cognition and how, in converse, D3 antagonists may exert pro-cognitive and antipsychotic effects.
Collapse
Affiliation(s)
- Clément E Lemercier
- Institute of Neurophysiology, Charité - Universitätsmedizin Berlin Berlin, Germany
| | - Steffen B Schulz
- Institute of Neurophysiology, Charité - Universitätsmedizin Berlin Berlin, Germany
| | - Karin E Heidmann
- Institute of Neurophysiology, Charité - Universitätsmedizin Berlin Berlin, Germany
| | - Richard Kovács
- Institute of Neurophysiology, Charité - Universitätsmedizin Berlin Berlin, Germany
| | - Zoltan Gerevich
- Institute of Neurophysiology, Charité - Universitätsmedizin Berlin Berlin, Germany
| |
Collapse
|
8
|
Delgado O, Delgado F, Vega JA, Trabanco AA. N-Bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders. Eur J Med Chem 2014; 97:719-31. [PMID: 25542766 DOI: 10.1016/j.ejmech.2014.12.034] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Revised: 12/16/2014] [Accepted: 12/19/2014] [Indexed: 12/21/2022]
Abstract
The search for novel heterobicyclic compounds within the drug-like chemical space continues to be an area of interest in medicinal chemistry. Unsaturated N-bridgehead heterocycles are well represented in marketed drugs for a variety of therapeutic areas, and continue to play an important role in central nervous system (CNS) drug discovery programs. Examples of medicinal chemistry strategies that make use of N-bridged 5,6-bicyclic pyridines are discussed here in this Minireview, which covers the literature from 2010 up to 2014. B1-class imidazopyridines and B3-class pyrazolopyridines have proven to be at the forefront of molecular prototypes that are capable of interacting with disease relevant targets in neurodegeneration and neuropsychiatry.
Collapse
Affiliation(s)
- Oscar Delgado
- Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain
| | - Francisca Delgado
- Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain
| | - Juan Antonio Vega
- Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain
| | - Andrés A Trabanco
- Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain.
| |
Collapse
|
9
|
Bartolomé-Nebreda JM, Delgado F, Martín-Martín ML, Martínez-Viturro CM, Pastor J, Tong HM, Iturrino L, Macdonald GJ, Sanderson W, Megens A, Langlois X, Somers M, Vanhoof G, Conde-Ceide S. Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia. J Med Chem 2014; 57:4196-212. [DOI: 10.1021/jm500073h] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- José Manuel Bartolomé-Nebreda
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Francisca Delgado
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - María Luz Martín-Martín
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Carlos M. Martínez-Viturro
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Joaquín Pastor
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Han Min Tong
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Laura Iturrino
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Gregor J. Macdonald
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Wendy Sanderson
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Anton Megens
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Xavier Langlois
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Marijke Somers
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Greet Vanhoof
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Susana Conde-Ceide
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| |
Collapse
|
10
|
Metabotropic Glutamate Receptor 2 Activators. SMALL MOLECULE THERAPEUTICS FOR SCHIZOPHRENIA 2014. [DOI: 10.1007/7355_2014_48] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
11
|
Constant É. Enjeux cliniques du passage d’un antipsychotique à l’autre. Encephale 2013; 39:439-44. [DOI: 10.1016/j.encep.2013.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2013] [Accepted: 09/13/2013] [Indexed: 01/07/2023]
|
12
|
|
13
|
Clarke WP, Chavera TA, Silva M, Sullivan LC, Berg KA. Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol 2013; 170:532-45. [PMID: 23826915 PMCID: PMC3791992 DOI: 10.1111/bph.12295] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 06/20/2013] [Accepted: 06/25/2013] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND AND PURPOSE Paliperidone is an active metabolite of the second-generation atypical antipsychotic, risperidone recently approved for the treatment of schizophrenia and schizoaffective disorder. Because paliperidone differs from risperidone by only a single hydroxyl group, questions have been raised as to whether there are significant differences in the effects elicited between these two drugs. EXPERIMENTAL APPROACH We compared the relative efficacies of paliperidone versus risperidone to regulate several cellular signalling pathways coupled to four selected GPCR targets that are important for either therapeutic or adverse effects: human dopamine D2 , human serotonin 2A receptor subtype (5-HT2A ), human serotonin 2C receptor subtype and human histamine H1 receptors. KEY RESULTS Whereas the relative efficacies of paliperidone and risperidone were the same for some responses, significant differences were found for several receptor-signalling systems, with paliperidone having greater or less relative efficacy than risperidone depending upon the receptor-response pair. Interestingly, for 5-HT2A -mediated recruitment of β-arrestin, 5-HT2A -mediated sensitization of ERK, and dopamine D2 -mediated sensitization of adenylyl cyclase signalling, both paliperidone and risperidone behaved as agonists. CONCLUSIONS AND IMPLICATIONS These results suggest that the single hydroxyl group of paliperidone promotes receptor conformations that can differ from those of risperidone leading to differences in the spectrum of regulation of cellular signal transduction cascades. Such differences in signalling at the cellular level could lead to differences between paliperidone and risperidone in therapeutic efficacy or in the generation of adverse effects.
Collapse
MESH Headings
- Adenylyl Cyclases/metabolism
- Animals
- Antipsychotic Agents/chemistry
- Antipsychotic Agents/pharmacology
- Arrestins/metabolism
- CHO Cells
- Cricetinae
- Cricetulus
- Dopamine Agonists/pharmacology
- Dose-Response Relationship, Drug
- Drug Inverse Agonism
- Extracellular Signal-Regulated MAP Kinases/metabolism
- Histamine Agonists/pharmacology
- Humans
- Isoxazoles/chemistry
- Isoxazoles/pharmacology
- Molecular Structure
- Paliperidone Palmitate
- Pyrimidines/chemistry
- Pyrimidines/pharmacology
- Receptor, Serotonin, 5-HT2A/drug effects
- Receptor, Serotonin, 5-HT2A/genetics
- Receptor, Serotonin, 5-HT2A/metabolism
- Receptor, Serotonin, 5-HT2C/drug effects
- Receptor, Serotonin, 5-HT2C/genetics
- Receptor, Serotonin, 5-HT2C/metabolism
- Receptors, Dopamine D2/drug effects
- Receptors, Dopamine D2/genetics
- Receptors, Dopamine D2/metabolism
- Receptors, Histamine H1/drug effects
- Receptors, Histamine H1/genetics
- Receptors, Histamine H1/metabolism
- Risperidone/chemistry
- Risperidone/pharmacology
- Serotonin Receptor Agonists/pharmacology
- Signal Transduction/drug effects
- Structure-Activity Relationship
- Transfection
- beta-Arrestins
Collapse
Affiliation(s)
- W P Clarke
- Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX, USA
| | | | | | | | | |
Collapse
|
14
|
Bartolomé-Nebreda JM, Conde-Ceide S, Delgado F, Iturrino L, Pastor J, Pena MÁ, Trabanco AA, Tresadern G, Wassvik CM, Stauffer SR, Jadhav S, Gogi K, Vinson PN, Noetzel MJ, Days E, Weaver CD, Lindsley CW, Niswender CM, Jones CK, Conn PJ, Rombouts F, Lavreysen H, Macdonald GJ, Mackie C, Steckler T. Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. J Med Chem 2013; 56:7243-59. [PMID: 23947773 PMCID: PMC3924858 DOI: 10.1021/jm400650w] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Starting from a singleton chromanone high throughput screening (HTS) hit, we describe a focused medicinal chemistry optimization effort leading to the identification of a novel series of phenoxymethyl-dihydrothiazolopyridone derivatives as selective positive allosteric modulators (PAMs) of the metabotropic glutamate 5 (mGlu5) receptor. These dihydrothiazolopyridones potentiate receptor responses in recombinant systems. In vitro and in vivo drug metabolism and pharmacokinetic (DMPK) evaluation allowed us to select compound 16a for its assessment in a preclinical animal screen of possible antipsychotic activity. 16a was able to reverse amphetamine-induced hyperlocomotion in rats in a dose-dependent manner without showing any significant motor impairment or overt neurological side effects at comparable doses. Evolution of our medicinal chemistry program, structure activity, and properties relationships (SAR and SPR) analysis as well as a detailed profile for optimized mGlu5 receptor PAM 16a are described.
Collapse
Affiliation(s)
| | - Susana Conde-Ceide
- Neuroscience Medicinal Chemistry, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Francisca Delgado
- Neuroscience Medicinal Chemistry, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Laura Iturrino
- CREATe Analytical Sciences, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Joaquín Pastor
- Neuroscience Medicinal Chemistry, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Miguel Ángel Pena
- Neuroscience Medicinal Chemistry, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Andrés A. Trabanco
- Neuroscience Medicinal Chemistry, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Gary Tresadern
- CREATe Molecular Informatics, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Carola M. Wassvik
- CREATe Molecular Informatics, Janssen Research and Development, Jarama 75, 45007 Toledo, Spain
| | - Shaun R. Stauffer
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, Tennessee 37232, United States
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - Satyawan Jadhav
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
| | - Kiran Gogi
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
| | - Paige N. Vinson
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
| | - Meredith J. Noetzel
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
| | - Emily Days
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - C. David Weaver
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - Craig W. Lindsley
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, Tennessee 37232, United States
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - Colleen M. Niswender
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, Tennessee 37232, United States
| | - Carrie K. Jones
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, Tennessee 37232, United States
| | - P. Jeffrey Conn
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, Tennessee 37232, United States
| | - Frederik Rombouts
- Neuroscience Medicinal Chemistry, Janssen Research and Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Hilde Lavreysen
- Neuroscience Biology, Janssen Research and Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Gregor J. Macdonald
- Neuroscience Medicinal Chemistry, Janssen Research and Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Claire Mackie
- CREATe Discovery ADME/Tox, Janssen Research and Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Thomas Steckler
- Neuroscience Biology, Janssen Research and Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| |
Collapse
|
15
|
Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013; 27:545-72. [PMID: 23821039 DOI: 10.1007/s40263-013-0079-5] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
With the widespread use of atypical or second-generation antipsychotics, switching treatment has become current practice and more complicated, as the pharmacological profiles of these agents differ substantially despite their similarity in being 'atypical'. All share the ability to block dopamine D₂ receptors, and most of them also block serotonin 5-HT2A receptors. Apart from these common features, some atypical antipsychotics are also able to block or stimulate other dopamine or serotonin receptors, as well as histaminergic, muscarinergic or adrenergic receptors. As a result of the varying receptor affinities, in switching or discontinuing compounds several possible pitfalls have to be considered, including the occurrence of withdrawal and rebound syndromes. This article reviews the pharmacological background of functional blockade or stimulation of receptors of interest in regard to atypical antipsychotics and the implicated potential withdrawal and rebound phenomena. A MEDLINE search was carried out to identify information on withdrawal or rebound syndromes occurring after discontinuation of atypical antipsychotics. Using the resulting literature, we first discuss the theoretical background to the functional consequences of atypical antipsychotic-induced blockade or stimulation of neurotransmitter receptors and, secondly, we highlight the clinical consequences of this. We then review the available clinical literature on switching between atypical antipsychotics, with respect to the occurrence of withdrawal or rebound symptoms. Finally, we offer practical recommendations based on the reviewed findings. The systematic evaluation of withdrawal or rebound phenomena using randomized controlled trials is still understudied. Knowledge of pharmacological receptor-binding profiles may help clinicians in choosing adequate switching or discontinuation strategies for each agent. Results from large switching trials indicate that switching atypical antipsychotics can be performed in a safe manner. Treatment-emergent adverse events during or after switching are not always considered to be, at least in part, associated with the pre-switch antipsychotic. Further studies are needed to substantiate the evidence gained so far on different switching strategies. The use of concomitant medication, e.g., benzodiazepines or anticholinergic drugs, may help to minimize symptoms arising from the discontinuation or switching of antipsychotic treatment.
Collapse
|
16
|
Schulz SB, Heidmann KE, Mike A, Klaft ZJ, Heinemann U, Gerevich Z. First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 2013; 167:1480-91. [PMID: 22817643 DOI: 10.1111/j.1476-5381.2012.02107.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND AND PURPOSE Disturbed cortical gamma band oscillations (30-80 Hz) have been observed in schizophrenia: positive symptoms of the disease correlate with an increase in gamma oscillation power, whereas negative symptoms are associated with a decrease. EXPERIMENTAL APPROACH Here we investigated the effects of first and second generation antipsychotics (FGAs and SGAs, respectively) on gamma oscillations. The FGAs haloperidol, flupenthixol, chlorpromazine, chlorprothixene and the SGAs clozapine, risperidone, ziprasidone, amisulpride were applied on gamma oscillations induced by acetylcholine and physostigmine in the CA3 region of rat hippocampal slices. KEY RESULTS Antipsychotics inhibited the power of gamma oscillations and increased the bandwidth of the gamma band. Haloperidol and clozapine had the highest inhibitory effects. To determine which receptor is responsible for the alterations in gamma oscillations, the effects of the antipsychotics were plotted against their pK(i) values for 19 receptors and analysed for correlation. Our results indicated that 5-HT(3) receptors have an enhancing effect on gamma oscillations whereas dopamine D(3) receptors inhibit them. To test this prediction, m-chlorophenylbiguanide, PD 128907 and CP 809101, selective agonists at 5-HT(3) , D(3) and 5-HT(2C) receptors were applied and revealed that 5-HT(3) receptors indeed enhanced the gamma power whereas D(3) receptors reduced it. As predicted, 5-HT(2C) receptors had no effects on gamma oscillations. CONCLUSION AND IMPLICATIONS Our data suggest that antipsychotics alter hippocampal gamma oscillations by interacting with 5-HT(3) and dopamine D(3) receptors. Moreover, a correlation of receptor affinities with the biological effects can be used to predict targets for the pharmacological effects of multi-target drugs.
Collapse
Affiliation(s)
- Steffen B Schulz
- Institute of Neurophysiology, Charité Universitätsmedizin Berlin, Berlin, Germany NeuroCure Research Centre, Charité Universitätsmedizin Berlin, Berlin, Germany
| | | | | | | | | | | |
Collapse
|